Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.37 |
| ▸ | SCN1A | P35498 | 2/20 | 0.37 |
| ▸ | SCN2B | O60939 | 1/20 | 0.37 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.37 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523542 | 0.93 | SCN9A (0.39) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL16094579 | 0.88 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL17509681 | 0.87 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL16120733 | 0.86 | SCN9A (0.34) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL16094574 | 0.85 | SCN9A (0.41) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL17509683 | 0.84 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL17961886 | 0.83 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL16120744 | 0.83 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL17739649 | 0.83 | SCN9A (0.39) | SCN9ASCN5ACYP2C9CYP3A4SCN8A | |
| SCHEMBL28074465 | 0.82 | SCN9A (0.41) | SCN9ASCN5ACYP2C9CYP3A4SCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105611923-B | Sodium channel modulators for the treatment of pain and diabetes | 卓莫赛尔公司 | 2019-08-23 | — | — | CN | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | CHROMOCELL CORPORATION | 2019-01-15 | — | — | US | disclosed |
| EP-3043787-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORP (US) | 2018-09-05 | — | — | EP | disclosed |
| EP-2968234-B1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORP (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3193610-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | Chromocell Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9458118-B2 | Sodium channel modulators for the treatment of pain and diabetes | CHROMOCELL CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| EP-3043787-A2 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | Chromocell Corporation (US) | 2016-07-20 | — | — | EP | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | CHROMOCELL CORPORATION (US) | 2016-05-12 | — | — | US | disclosed |
| WO-2016040315-A1 | SELECTIVE NAV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | CHROMOCELL CORPORATION (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2016-02-18 | — | — | US | disclosed |
| EP-2968234-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | Chromocell Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151472-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | CHROMOCELL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130239-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN AND DIABETES | SCN7A, SCN1A, SCN10A | SCN9A 11/4885SCN5A 8/4885CYP2C9 2365/4885 |
| US-10179781-B2 | Sodium channel modulators for the treatment of pain | SCN7A, SCN10A, SCN2A | SCN9A 13/4885SCN5A 10/4885CYP2C9 1865/4885 |
| US-20160046617-A1 | SODIUM CHANNEL MODULATORS FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, SCN2A | SCN9A 13/4885SCN5A 10/4885CYP2C9 1865/4885 |
| US-20170304306-A1 | SELECTIVE NaV1.7 INHIBITORS FOR THE TREATMENT OF DIABETES | SCN7A, SCN1A, SCN1B | SCN9A 5/4885SCN5A 4/4885CYP2C9 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.